Silent celiac disease in chronic hepatitis C: Impact of interferon treatment on the disease onset and clinical outcome

Journal of Clinical Gastroenterology

Volumn 38, Issue 10, 2004, Pages 901-905

  Durante Mangoni, Emanuele ^a   Iardino, Patrizia ^a   Resse, Marianna ^a   Cesaro, Giuseppe ^a   Sica, Antonello ^a   Farzati, Bartolomeo ^a   Ruggiero, Giuseppe ^a   Adinolfi, Luigi E ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Celiac disease; Hepatitis C; HLA antigens; Interferon

Indexed keywords

ALPHA INTERFERON; ENZYME ANTIBODY; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; LYMPHOBLAST INTERFERON; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNITY; CELIAC DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGE OF ONSET; AGED; ANTIVIRAL AGENTS; AUTOANTIBODIES; CELIAC DISEASE; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSGLUTAMINASES; TREATMENT OUTCOME;

EID: 6944222729     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200411000-00014     Document Type: Article

References (29)

1. Kim WR, Brown RS Jr, Terrault NA, et al. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227-242.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
3. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;21:613-619.
4. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490-1495.
5. Adinolfi LE, Utili R, Attanasio V, et al. Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol. 1996;28:1-9.
6. Pawlotsky JM, Dhumeaux D, Bagot M. Hepatitis C virus in dermatology: a review. Arch Dermatol. 1995;131:1185-1193.
7. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993;18:253-257.
8. Jorgensen C, Legouffe MC, Perney P, et al. Sicca syndrome associated with hepatitis C virus infection. Arthritis Rheum. 1996;39:1166-1171.
9. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002;36(suppl):3-20.
10. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha-interferon. J Hepatol. 1996;24:38-47.
11. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(suppl):112-121.
12. Reddy RK, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001;33:433-438.
13. Bardella MT, Marino R, Meroni PL. Coeliac disease during interferon treatment. Ann Intern Med. 1999;131:157-158.
14. Adinolfi LE, Durante Mangoni E, Andreana A. Interferon and ribavirin treatment for chronic hepatitis C may activate coeliac disease. Am J Gastroenterol. 2001;96:606-607.
15. Cammarota G, Cuoco L, Cianci R, et al. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet. 2000;356:1494-1495.
16. Bourliere M, Oules V, Perrier H, et al. Onset of coeliac disease and interferon treatment. Lancet. 2001;357:803-804.
17. Monteleone G, Pender SL, Alstead E, et al. Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut. 2001;48:425-429.
18. Fasano A, Catassi C. Current approaches to diagnosis and treatment of coeliac disease: an evolving spectrum. Gastroenterology. 2001;120:636-651.
19. Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of coeliac disease. Nat Med. 1997;3:797-801.
20. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol. 2002;2:647-655.
21. Arentz-Hansen H, Korner R, Molberg O, et al. The intestinal T cell response to alpha-gliadin in adult coeliac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med. 2000;191:603-612.
22. Murray JA, Van Dyke C, Plevak MF, et al. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol. 2003;1:19-27.
23. Volta U, Bellentani S, Bianchi FB, et al. High prevalence of coeliac disease in Italian general population. Dig Dis Sci. 2001;46:1500-1505.
24. Fine KD, Ogunji F, Saloum Y, et al. Coeliac sprue; another autoimmune syndrome associated with hepatitis C. Am J Gastroenterol. 2001;96:138-145.
25. Manns MP, Obermayer-Straub P. Viral induction of autoimmunity: mechanisms and examples in hepatology. J Viral Hepatol. 1997;4(suppl 2):42-47.
26. Nilsen EM, Lundin KE, Krajci P, et al. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut. 1995;37:766-776.
27. Nilsen EM, Jahnsen FL, Lundin KE, et al. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with coeliac disease. Gastroenterology. 1998;115:551-563.
28. Salvati VM, MacDonald TT, Bajaj-Elliott M, et al. Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut. 2002;50:186-190.
29. Hultgren C, Milich D, Weiland O, et al. The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C vims-specific immune responses. J Gen Virol. 1998;79:2381-2391.